Autolus Therapeutics plc
AUTL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001730463
In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Autolus Therapeutics plc changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 65 | 1 | 69 | +5 |
| Shares | 106.1M | 2.50M | 109.4M | +5.84M (+5.6%) |
| Value | $195.1M | $4.60M | $260.4M | +$69.8M (+36.6%) |
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held Autolus Therapeutics plc at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 9,217,150 | $21.9M | 1.78% |
| Affinity Asset Advisors, LLC | 1,589,017 | $3.78M | 1.49% |
| Odey Asset Management LLP | 658,995 | $1.57M | 0.58% |
| Edentree Asset Management Ltd | 180,000 | $430.2K | 0.15% |
| Alps Advisors Inc | 127,220 | $302.8K | 0.00% |
| Mariner, LLC | 101,000 | $240.0K | 0.00% |
| Exchange Traded Concepts, LLC | 49,527 | $117.9K | 0.00% |
| Marshall Wace, LLP | 25,496 | $60.7K | 0.00% |
| National Asset Management, Inc. | 22,000 | $52.4K | 0.00% |
| Qube Research & Technologies Ltd | 21,907 | $52.1K | 0.00% |
| Invesco Ltd. | 10,699 | $25.5K | 0.00% |
| Rhumbline Advisers | 1,228 | $2.92K | 0.00% |
| Northwestern Mutual Wealth Management Co | 100 | $238 | 0.00% |
Sold out (8)
Institutions that held Autolus Therapeutics plc at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Millennium Management LLC | 360,145 | $663.0K |
| Alyeska Investment Group, L.P. | 214,300 | $394.3K |
| Cubist Systematic Strategies, LLC | 133,860 | $246.3K |
| Boulder Hill Capital Management LP | 57,191 | $105.2K |
| Susquehanna International Group, LLP | 38,947 | $71.7K |
| Cannell Capital LLC | 16,835 | $31.0K |
| Acadian Asset Management LLC | 12,192 | $22.0K |
| Bayshore Asset Management, LLC | 10,000 | $18.4K |
Not filed for Q2 2023 yet (1)
Institutions that held Autolus Therapeutics plc at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Odey Asset Management Group Ltd | 2,499,400 | $4.60M |